In this cross-sectional study, serum asprosin levels were measured in middle-aged patients with AGHD to investigate the impact of GH/IGF-1 deficiency on asprosin levels and to examine potential biomarkers of metabolic disorders associated with GH/IGF-1 deficiency by establishing correlations between serum asprosin levels and metabolic parameters. This evidence concerns the gene GH1 and Other metabolic disease.